SpringWorks Therapeutics Price Target Lowered to $55 From $58 at BofA
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
